A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

NCT02794519 | Withdrawn Phase 2

• 1 other identifier: 205076
• Study Type: interventional
• Target: N/A
• Locations: 2 countries
• Sites: 8

Brief Summary

Sirukumab is a fully human anti interleukin (IL)-6 immunoglobulin G1-kappa monoclonal antibody (MAb) which is in development for the treatment of rheumatoid arthritis (RA). The continuing unmet need in subjects with asthma refractory to corticosteroid therapy and increased understanding of asthma pathogenesis have stimulated the development of targeted biologics based on predictive biomarkers. The majority of approaches to date have targeted T Helper 2 (Th2) cytokines or their downstream effects. Targeting IL-6 in severe asthma represents an unprecedented approach that has potential to address non-Th2 drivers of severe asthma. This multicenter, randomized, double-blind (sponsor-unblind), placebo-controlled, parallel group study will investigate the efficacy of sirukumab compared to placebo in subjects having uncontrolled severe asthma despite use of high dose inhaled corticosteroid (ICS) in combination with long-acting Beta-agonist (LABA). The study will employ a variable treatment period for individual subjects. Dosing will continue every 4 weeks until week 44 (inclusive), or until 24 weeks after the final subject has been randomized, whichever the sooner. Upon receiving the final dose of study medicine or placebo, subjects will enter a 16 week Follow Up period. Overall, the duration of participation for subjects who complete the full 44-week treatment period and Follow Up period may be up to 64 weeks. Approximately 175 subjects will be randomized such that 140 evaluable subjects complete the study.

Conditions

Asthma

Keywords

Asthma Control Questionnaire; interleukin-6; Sirukumab; severe, poorly controlled asthma; asthma; ACQ

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Week 24

  The ACQ-7 is a seven-item questionnaire that is a measure of a subject's asthma control. Six of the questions will be self-completed by the subject, recalling over the previous 7 days. The six questions enquire about the frequency and/or severity of symptoms (nocturnal awakening, activity limitation, shortness of breath and wheeze), and rescue bronchodilator use. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale. The final question is a rating of forced expiratory volume in 1 second FEV1% predicted. The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). Baseline value is the value obtained at Day 1 before administration of investigational product (IP). Change from baseline in ACQ-7 score will be analysed using a Bayesian repeated measures model.

  Baseline and Week 24

Secondary Outcomes (20)

• Safety as assessed by number of subjects with adverse events (AE) and serious adverse events (SAE)

  Up to 60 Weeks

• Safety as assessed by body temperature

  Up to 60 Weeks

• Safety as assessed by systolic and diastolic blood pressure

  Up to 60 Weeks

• Safety as assessed by pulse rate

  Up to 60 Weeks

• Safety as assessed by electrocardiogram (ECG)

  Up to 60 Weeks

Study Arms (2)

Sirukumab 50 mg/mL administered subcutaneously every 4 weeks

EXPERIMENTAL

Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.

Drug: Sirukumab; Drug: Rescue medication

Placebo administered subcutaneously every 4 weeks

PLACEBO COMPARATOR

Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.

Drug: Placebo; Drug: Rescue medication

Interventions

Sirukumab DRUG

This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.

Sirukumab 50 mg/mL administered subcutaneously every 4 weeks

Placebo DRUG

This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.

Placebo administered subcutaneously every 4 weeks

Rescue medication DRUG

Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.

Placebo administered subcutaneously every 4 weeks; Sirukumab 50 mg/mL administered subcutaneously every 4 weeks

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects aged 18 - 75 years, inclusive.
• Severe, uncontrolled asthma according to the following criteria: Physician-diagnosed asthma for \>=12 months, and; treatment for at least 3 months with \>=880 microgram per day of fluticasone propionate (FP) dry powder for inhalation (DPI) or its equivalent, plus a long acting beta agonist (LABA), and' ACQ-7 score \>=1.5, and; a documented history (e.g., medical record verification) in the 12 months prior to Visit 2 of \>=1 exacerbation resulting in prescription for systemic oral corticosteroids or hospitalisation or extended observation in a hospital emergency room or outpatient centre. \[For subjects on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required\] and; pre-bronchodilator FEV1 35-80% inclusive, with evidence of \>=12% (and 200 milliliter \[mL\]) reversibility in FEV1 measured 15-30 minutes following 4 actuations of salbutamol (100 microgram per actuation) or albuterol (90 microgram per actuation) via pre-metered dose inhaler (pMDI). This reversibility criterion should have been documented in the 12-months prior to Screening. If no prior data are available this should be demonstrated either at Screening (Visit 2) or at the Randomization visit (Visit 3); blood eosinophil count \<300 cells per microliter at screening.
• Body mass index 18-45 kilogram per meter square.
• Male or Females and Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until a cycle of spermatogenesis following five terminal half- lives after the last dose of study medication: Vasectomy with documentation of azoospermia; Male condom plus partner use of one of the following contraceptive options: Contraceptive subdermal implant; Intrauterine device or intrauterine system; Combined estrogen and progestogen oral contraceptive; Injectable progesterone; Contraceptive vaginal ring; Percutaneous contraceptive patches.
• This is an all-inclusive list of those methods that meet the following GlaxoSmithKline (GSK) definition of highly effective: having a failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. For non-product methods (e.g., male sterility), the investigator determines what is consistent and correct use. The GSK definition is based on the definition provided by The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
• The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
• A female subject is eligible to participate if she is of non-child bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as age greater than 60 or 12 months of spontaneous amenorrhea with an appropriate clinical profile \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \>40 milliinternational units per milliliter (MlU/mL) and estradiol \<40 picogram per milliliter (pg/mL) (\<140 picomole per liter \[pmol/L\] is confirmatory) or if of child-bearing potential is using a highly effective method for avoidance of pregnancy for the duration of dosing and until 4 months post last-dose.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

You may not qualify if:

• Presence of a known pre-existing, clinically important lung condition other than asthma. This includes chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer.
• Lower respiratory tract infection (LRTI) or asthma exacerbation requiring antibiotics or systemic corticosteroids within 6 weeks of screening.
• Evidence of respiratory infection at screening.
• Has a history of chronic or recurrent infectious disease or ongoing infection including, but not limited to, chronic renal infection, chronic chest infection, recurrent urinary tract infection (example, recurrent pyelonephritis, chronic non-remitting cystitis), or open, draining skin wound or an ulcer.
• Serious infection within 8 weeks of enrolment, including, but not limited to hepatitis, pneumonia, sepsis, or pyelonephritis; or has been hospitalized for an infection; or has been treated with intravenous (IV) antibiotics for an infection, within 8 weeks prior to the first administration of study drug.
• Opportunistic infection, example, a nontuberculous mycobacterial infection or cytomegalovirus, pneumocystosis, aspergillosis within 6 months prior to screening.
• Evidence of poorly controlled chronic medical conditions other than asthma, example, subjects with known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, and haematological or any other system abnormalities that are uncontrolled with standard treatment.
• Current history of suicidal ideation or a past history of suicide attempt.
• Lactating, pregnant, or planning to become pregnant during the study.
• Malignancy within 5 years (except local basal cell carcinoma, or fully excised local dermal, squamous cell carcinoma).
• Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis.
• Has a history of gastrointestinal perforation or currently has active diverticulitis.
• QTcorrected (QTc) \>450 milliseconds (msec) or QTc \>480 msec in subjects with Bundle Branch Block. Notes: The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB), Fridericia's formula (QTcF), and/or another method, machine-read or manually over-read; The specific formula that will be used to determine eligibility and discontinuation for an individual subject should be determined prior to initiation of the study. In other words, several different formulae cannot be used to calculate the QTc for an individual subject and then the lowest QTc value used to include or discontinue the subject from the trial.
• Alanine transaminase (ALT) \>1.5 times upper limit of normal (ULN) and bilirubin \>ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• Laboratory abnormalities: Neutrophils \<1.95 multiplied by 10 raise to 9 per liter; Platelet count \<140 multiplied by 10 raise to 9 per liter; Hemoglobin \<8.5 grams per decilitre (g/dL); WBC count \<3.5 × multiplied by 10 raise to 9 per liter.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (8)

GSK Investigational Site

Long Beach, California, 90808, United States

Location

GSK Investigational Site

Aventura, Florida, 33180, United States

Location

GSK Investigational Site

Cincinnati, Ohio, 45231, United States

Location

GSK Investigational Site

Richmond, Virginia, 23225, United States

Location

GSK Investigational Site

Richmond, Virginia, 23229, United States

Location

GSK Investigational Site

Alcorcón (Madrid), 28922, Spain

Location

GSK Investigational Site

Girona, 17005, Spain

Location

GSK Investigational Site

Santiago de Compostela. La Coruña., 15706, Spain

Location

MeSH Terms

Conditions

Asthma

Interventions

sirukumab

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2016
• First Posted: June 9, 2016
• Study Start: September 23, 2016
• Primary Completion: October 4, 2016
• Study Completion: October 4, 2016
• Last Updated: August 31, 2018

Record last verified: 2018-08

Locations

US (5); ES (3)